Clinical Trials
29
13 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Active, not recruiting
12
41.4%
Available
1
3.5%
Completed
2
6.9%
Enrolling By Invitation
1
3.5%
Recruiting
9
31.0%
Terminated
3
10.3%
Withdrawn
1
3.5%
No approval data available
- The FDA approved obecabtagene autoleucel (Aucatzyl) for adults with relapsed or refractory B-cell precursor ALL, marking a significant advancement in CAR T-cell therapy. - A pivotal clinical trial revealed transformative findings poised to change the standard of care for children with acute lymphoblastic leukemia (ALL), marking a milestone in pediatric oncology. - Pfizer's BESPONSA received FDA approval for pediatric patients aged 1 year and older with relapsed or refractory CD22-positive B-cell ALL, expanding treatment options for this population.
- Three patients in the UK have received CAR T-cell therapy for severe lupus, a potentially life-threatening autoimmune disease. - Early results from a German study showed that patients who underwent CAR T-cell therapy are now in remission and do not require lupus medication. - The NHS trial, led by UCLH and UCL, modifies cells to enable the immune system to recognize and attack problem cells, offering a possible cure. - Researchers are optimistic that this one-time treatment could revolutionize lupus care, potentially eliminating the need for lifelong medication.
- Three patients in the UK have received CAR T-cell therapy for severe lupus, offering a potential cure and eliminating the need for lifelong medication. - The NHS trial, led by UCLH and UCL, uses genetically modified cells to target and attack problem cells, showing early indications of revolutionizing lupus treatment. - Patients who underwent CAR T-cell therapy in Germany have achieved remission and discontinued lupus drugs, demonstrating the therapy's potential for long-term benefits. - The CAR T-cell therapy, obecabtagene autoleucel (obe-cel), is being evaluated in a clinical trial sponsored by Autolus Limited, with hopes of replicating positive outcomes.
- Three UK patients have received CAR T-cell therapy for severe lupus, offering hope for a potential cure and eliminating the need for lifelong medication. - The treatment, which modifies the immune system to target problem cells, has shown promising early results, with some patients achieving drug-free remission. - The CAR T-cell therapy trial, led by University College London Hospitals NHS Foundation Trust, aims to replicate positive outcomes seen in earlier German studies. - The therapy involves programming CAR T cells to target overactive B cells, which cause the body to attack its own tissues in lupus patients.
- Three patients in the UK have received CAR T-cell therapy for severe lupus, a potentially life-threatening autoimmune condition, in a new NHS trial led by UCLH and UCL. - Early results from a German study indicate that CAR T-cell therapy could induce drug-free remission in lupus patients, offering a possible cure and revolutionizing treatment. - The CAR T-cell therapy involves genetically modifying a patient's own immune cells to target and eliminate the cells causing lupus, potentially correcting the underlying defect of the disease. - The clinical trial, sponsored by Autolus Limited, will follow patients for 15 years to fully assess the long-term effects of obecabtagene autoleucel (obe-cel) in treating lupus.
- Big Pharma's traditional R&D model is shifting towards external innovation, with universities and biotech spin-outs becoming essential players in drug development ecosystem. - Early-stage biotech spin-outs require careful timing, substantial proof-of-principle data, and experienced management to successfully bridge academic research and commercial development. - New funding initiatives from MRC/TSB Biomedical Catalyst and Wellcome Trust's Syncona Fund are helping address the financing challenges faced by UK biotech spin-outs.
